

# Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

## SK-UT-1B

RRID:CVCL\_2250

Type: Cell Line

### Proper Citation

RRID:CVCL\_2250

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_2250](https://web.expasy.org/cellosaurus/CVCL_2250)

**Proper Citation:** RRID:CVCL\_2250

**Description:** Cell line SK-UT-1B is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Uterine corpus leiomyosarcoma

**Defining Citation:** [PMID:327080](#), [PMID:2372783](#), [PMID:2766249](#), [PMID:3383166](#), [PMID:3518877](#), [PMID:6935474](#), [PMID:9541971](#), [PMID:25877200](#), [PMID:26351324](#), [PMID:28196595](#)

**Comments:** Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** SK-UT-1B

**Synonyms:** SKUT1B, SK-UT 1B, SKUT-1B, Skut1B

**Cross References:** BTO:BTO\_0003725, CLO:CLO\_0009066, CLDB:cl4359, ATCC:HTB-115, BioSample:SAMN03471096, BioSample:SAMN03472878, cancercellines:CVCL\_2250, CancerTools:161939, ChEMBL-Cells:ChEMBL3307682, ChEMBL-Targets:ChEMBL614678, CLS:300406, Cosmic:713478, Cosmic:871555, Cosmic:889118, Cosmic:1007164, Cosmic:1066227, Cosmic:1091505, GEO:GSM185152, GEO:GSM185153, GEO:GSM844693, GEO:GSM844694, GEO:GSM1676334, GEO:GSM1701666, IGRhCellID:SKUT1B, IZSLER:BS TCL 210, Progenetix:CVCL\_2250, PubChem\_Cell\_line:CVCL\_2250, Wikidata:Q54954651

**ID:** CVCL\_2250

**Hierarchy:** cvcl\_0533

**Record Creation Time:** 20220427T221548+0000

**Record Last Update:** 20260920T005756+0000

---

## Ratings and Alerts

No rating or validation information has been found for SK-UT-1B.

No alerts have been found for SK-UT-1B.

---

## Data and Source Information

**Source:** [CelloSaurus](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3864.